Andrew I. McDonald net worth and biography

Andrew McDonald Biography and Net Worth

Director of Vincerx Pharma
Andrew McDonald, PhD is a member of Vincerx’s board of directors. Dr McDonald has served as chief executive officer and as a member of the board of directors of LSAC since June 2019. Dr McDonald has served as chief executive officer of Attune Pharmaceuticals, a clinical-stage biotechnology company, since March 2015 and is a founding partner of LifeSci Advisors, LLC, a life sciences investor relations consultancy company, and LifeSci Capital, LLC, an emerging life sciences investment bank. Before founding LifeSci Advisors, LLC, and LifeSci Capital, LLC, in March 2010, Dr McDonald served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008. From 2004 to 2006, Dr McDonald served as head of healthcare research and a biotechnology analyst at ThinkEquity Partners, a boutique investment bank. Before entering the financial services industry, Dr McDonald was a medicinal chemist at Cytokinetics, Inc., a biopharmaceutical company, from 2001 to 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Dr McDonald began his pharmaceutical career as a medicinal chemist at Pfizer. Dr McDonald received a PhD in organic chemistry from University of California, Irvine and completed his BS in chemistry at University of California, Berkeley. Dr McDonald holds Series 7, 24, 63, 79, 86, and 87 licenses.

How do I contact Andrew I. McDonald?

The corporate mailing address for Dr. McDonald and other Vincerx Pharma executives is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. Vincerx Pharma can also be reached via phone at 650-800-6676. Learn More on Andrew I. McDonald's contact information.

Has Andrew I. McDonald been buying or selling shares of Vincerx Pharma?

Andrew I. McDonald has not been actively trading shares of Vincerx Pharma in the last ninety days. Learn More on Andrew I. McDonald's trading history.

Who are Vincerx Pharma's active insiders?

Vincerx Pharma's insider roster includes Laura Bushnell (Director), Ahmed Hamdy (CEO), Raquel Izumi (Insider), Andrew McDonald (Director), Alexander Seelenberger (CFO), and Tom Thomas (Insider). Learn More on Vincerx Pharma's active insiders.

Are insiders buying or selling shares of Vincerx Pharma?

During the last year, Vincerx Pharma insiders bought shares 8 times. They purchased a total of 109,869 shares worth more than $274,555.74. The most recent insider tranaction occured on August, 24th when Director Christopher P Lowe bought 18,400 shares worth more than $30,360.00. Insiders at Vincerx Pharma own 23.6 % of the company. Learn More about insider trades at Vincerx Pharma.

Information on this page was last updated on 8/24/2022.

Andrew I. McDonald Insider Trading History at Vincerx Pharma

See Full Table

Andrew I. McDonald Buying and Selling Activity at Vincerx Pharma

This chart shows Andrew I. Mcdonald's buying and selling at Vincerx Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vincerx Pharma Company Overview

Vincerx Pharma logo
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $0.70
Low: $0.66
High: $0.71

50 Day Range

MA: $1.00
Low: $0.67
High: $1.38

2 Week Range

Now: $0.70
Low: $0.65
High: $11.42

Volume

81,995 shs

Average Volume

175,528 shs

Market Capitalization

$14.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78